Steven P. Coen - 05 Oct 2026 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Reporting relationship: Chief Financial Officer
Issuer ticker: DNA
Reported as of: 05 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2026, 17:00:30 UTC
Prior SEC filing: 25 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Karen Tepichin, Attorney-in-Fact

Key filing fact

Steven P. Coen filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 07 Oct 2026.

Key facts

This page summarizes Steven P. Coen's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2026, 17:00.

Change

Previous filing in this sequence was filed on 25 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001977441 Primary reporting owner

Coen Steven P.

Relationship: Chief Financial Officer
Address: C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNA transaction

Class A Common Stock

Sale

Transaction value
Shares: -2,403
Change %: -4.6%
Price: $15.00^*
Shares after: 49,448
Date: 05 Oct 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934

SEC remarks

Chief Financial Officer